MAM
Bhavin Mukund Mehta takes charge as vice-chairman of Pharmexcil
MUMBAI: The Indian pharmaceutical industry just got a major upgrade! The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has named Bhavin Mukund Mehta, Kilitch Drugs (India) Limited wholetime director, as its new vice-chairman. With over 25 years of industry experience, Mehta’s leadership is set to supercharge India’s global pharmaceutical exports.
A deal-making, strategy-shaping, market-expanding powerhouse, Mehta has not only catapulted Kilitch Drugs onto the global stage but also reinforced its domestic stronghold. Now, at Pharmexcil, he’s gearing up to break new ground, fuel innovation, and champion MSMEs—because, let’s face it, even the biggest industry players were once small businesses with big dreams.
Mehta’s association with Pharmexcil isn’t new—he’s practically been its MVP for years. Back in 2012, he was appointed as the chairman of the Exhibition Committee by the Ministry of Commerce, where he didn’t just organise trade events—he launched IPHEX, India’s largest pharmaceutical export exhibition, proving that India’s pharma game isn’t just strong, it’s global.
From negotiating high-stakes trade deals to ensuring Indian pharma gets its well-deserved global spotlight, Mehta has been the industry’s go-to expert. His latest appointment as vice-chairman of Pharmexcil? Just the logical next step in his mission to put Indian pharma on every international shelf possible.
Expressing his gratitude, Mehta said, “I am truly honoured to be appointed as vice-chairman at Pharmexcil. While promoting the growth of pharmaceutical exports, I am also committed to promoting the growth of MSMEs within India’s pharmaceutical sector, which plays a vital role in enhancing global health. Together, we will work to unlock new opportunities, drive innovation, and strengthen India’s position as a leader in pharmaceutical exports worldwide.”
Mehta isn’t just about business—he’s got the credentials to back it up. He holds a post graduate diploma in management from S.P. Jain Institute of Management, Mumbai, and a bachelor of pharmaceutical sciences from the University of Mumbai. His unique blend of technical knowledge and business acumen has been instrumental in navigating regulatory landscapes, executing expansion strategies, and driving pharmaceutical innovations.
With his appointment, Pharmexcil is set for a dynamic shift, championing not just large-scale pharma players but also boosting MSMEs that form the backbone of India’s pharmaceutical ecosystem.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
